IL6 and Alzheimer disease: Liu et al. [72] administered BMSCs-EXOs into the lateral ventricle and inhibited the excessive activation of microglia and astrocytes in the AD model mice hippocampus, simultaneously reducing the level of IL-1β, IL-6, TNF-α, synaptic-related proteins, and increasing BDNF protein levels.